<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92525">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01900431</url>
  </required_header>
  <id_info>
    <org_study_id>ACT13480</org_study_id>
    <secondary_id>2012-004845-34</secondary_id>
    <secondary_id>U1111-1130-6500</secondary_id>
    <nct_id>NCT01900431</nct_id>
  </id_info>
  <brief_title>Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis</brief_title>
  <acronym>SARILNIUSATURN</acronym>
  <official_title>A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of sarilumab at week 16 in patients with non-infectious uveitis
      (NIU).

      Secondary Objectives:

      To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of
      subcutaneous sarilumab in patients with NIU. To evaluate the change in macular edema. To
      evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal
      vessel leakage. To evaluate the effect of sarilumab on reducing concomitant
      immunosuppressant therapy.

      To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the
      pharmacokinetics of sarilumab in NIU patients. To evaluate the immunogenicity with anti-drug
      antibodies (ADA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration per patient is up to 58 weeks, which includes a 2 week screening period,
      16 weeks principal treatment period, 34 weeks extension treatment period (or open label
      treatment period), and 6 weeks after last treatment administration.

      Non-responder patients, observed within the first 16 weeks, will be offered to be treated by
      open-label sarilumab. Patients will be treated for 34 extra weeks (up to 18 extra
      injections).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with at least 2-step reduction in Vitreous Haze OR dose of prednisone &lt; 10 mg/day</measure>
    <time_frame>At 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in VH</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with anterior chamber score = 0 or at least 2-step reduction in score (Tyndall and flare according to the SUN classification)</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA (ETDRS letters score)</measure>
    <time_frame>Up to 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central retinal thickness measured with Optical Coherence Tomography (OCT)</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Central Retinal Thickness &lt;300 microns</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without retinal vessel leakage on fluorescein angiography compared to baseline</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with dose of prednisone ≤ 5mg/day (or equivalent oral corticosteroid)</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics assessment</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events including Serious Adverse Events and Adverse Events of Special Interest</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical laboratory data</measure>
    <time_frame>At 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191/REGN88)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One subcutaneous injection every 14 days up to 50 weeks.
Prednisone or equivalent steroid (as single therapy or in combination with methotrexate/folic acid) are continued as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarilumab (SAR153191/REGN88) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One subcutaneous injection every 14 days up to 50 weeks.
Prednisone or equivalent steroid (as single therapy or in combination with methotrexate/folic acid) are continued as background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarilumab SAR153191/REGN88</intervention_name>
    <description>Pharmaceutical form:Prefilled syringes Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab (SAR153191/REGN88)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191/REGN88)</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191/REGN88) Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Sarilumab (SAR153191/REGN88)</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191/REGN88) Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic/folinic acid</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Sarilumab (SAR153191/REGN88)</arm_group_label>
    <arm_group_label>Sarilumab (SAR153191/REGN88) Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sarilumab (SAR153191/REGN88) placebo</intervention_name>
    <description>Pharmaceutical form:Prefilled syringes Route of administration: subcutaneous</description>
    <arm_group_label>Sarilumab (SAR153191/REGN88) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        ≥18 years of age. Non-infectious intermediate-, posterior-, or pan-uveitis in the study
        eye. Active disease at screening or evidence of activity within the 3 months prior to
        screening visit. Following the approval of Amendment 2, only patients with &quot;active
        disease&quot; as defined above will be enrolled in the study.

        Starting oral prednisone dose must be greater than or equal to 15 mg/day and less than 80
        mg/day.

        At screening, patients must be receiving oral prednisone (≥15 mg and &lt; 80 mg/day [or
        equivalent oral corticosteroid]) as single immunosuppressive therapy or in combination
        with Methotrexate (MTX) (≤ 25 mg/week) orally or intravenously or intra muscular or
        subcutaneous). Patients can be receiving one or several of the following therapies:
        Azathioprine (≤2.5 mg/kg/day), Mycophenolate mofetil (≤2g daily, orally), Cyclosporine (≤4
        mg/kg daily, orally), Tacrolimus (≤4 mg daily, orally).

        The doses may not have been increased for at least 4 weeks prior to the randomization
        visit.

        At randomization, patients have been receiving oral prednisone (≥15 mg and &lt; 80 mg/day [or
        equivalent oral corticosteroid]) as single immunosuppressive therapy or in combination
        with methotrexate (MTX) (≤ 25 mg/week) orally or intravenously or intra muscular or
        subcutaneous).

        Azathioprine, mycophenolate mofetil, cyclosporine and tacrolimus have to be permanently
        discontinued at least 48 hours prior to the first study treatment injection, or longer as
        per Investigator's judgment. These immunomodulatory therapy (IMTs) are not permitted
        anytime during the treatment period.

        Signed written informed consent.

        Exclusion criteria:

        Patient with best-corrected visual acuity worse than 20 ETDRS letters in at least one eye.

        Patient with confirmed or suspected uveitis of infectious etiology or uveitis of traumatic
        etiology.

        Patient with primary diagnosis of anterior uveitis. Prior treatment with anti-IL-6 or
        IL-6R antagonist therapies, including tocilizumab and sarilumab.

        The above information is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840009</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Slingerlands</city>
        <state>New York</state>
        <zip>12159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203001</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 203002</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380004</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792001</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792005</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792002</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792003</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792004</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792006</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 26, 2016</lastchanged_date>
  <firstreceived_date>July 11, 2013</firstreceived_date>
  <firstreceived_results_disposition_date>March 7, 2016</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
